PCSK9抑制剂在冠心病患者中的研究现状

穆耶塞尔 阿卜拉1, 李秀 芬2
1.新疆医科大学第四临床医学院 乌鲁木齐 830000 2.新疆医科大学附属中医医院心内科 乌鲁木齐 830000

摘要

摘要:高脂血症是冠心病的重要危险因素，降脂治疗是冠心病治疗的重要内容。近些年来，PCSK9抑制剂被证实具有强效的降低低密度脂蛋白胆固醇的作用，并被多个降脂指南推荐作为降脂治疗的重要方法。大量研究表明，PCSK9抑制剂除具有降低LDL-C作用外，还发挥一定程度的抗炎作用，并显著降低心血管不良事件发生，且具有良好的安全性和耐受性。本文通过查阅国内外相关文献，就以PCSK9抑制剂在冠心病患者中的研究现状做阐述。

关键词

关键词:PCSK9抑制剂;冠心病;炎症因子

参考

[1]uparelia N, Chai JT, Fisher EA, et al. Inflammatory processes incardiovascular disease: a route to targeted therapy-es[J]. Nat Rev Cardiol,2017,14:133–44.[2]Ference BA,Kastelein, JJP,Catapano AL. Lipids and Lipoproteins in 2020[J]. JAMA, 2020, 324(6), 595-596.[3]MundiS,MassaroM,Scoditti E,et al Endothelial permeability,LDLdeposition,and cardiovascular risk factors-a review[J]. Cardiovasc. Res., 2018, 114(1), 35-52.[4]Liberale L,Dallegri F,MontecuccoF,et al. Pathophysiological relevance of macrophage subsets in atherogenesis. Thromb. Haemost., 2017, 117(1), 7-18.[5]chrijversDM,De MeyerRY,et al.Phagocytosis of apopto-tic cells by macrophages is impaired in atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2005, 25(6), 1256-1261.[6]Abifadel M, Varret M, Rabe`s JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154–156.[7]KentST,Rosenson RS, Avery CL, et al. PCSK9 loss-of-function variants,lo-w-densitylipoprotein cholesterol,andrisk of coronary heart disease and str-oke:data from9 studies of Blacks and Whites.Circ Cardiovasc Genet 2017;10:e001632.[8]RosensonRS,HegeleRA,FazioS,etal.The evolving futu-re of PCSK9inhibitors[J].Am Col.Cardiol.2018, 72(3), 314-329.[9]Ruscica M, TokgözoğluL, CorsiniA,et al.PCSK9 inhibition and inflammation: A narrative review[J]. Atheroscleros-is, 2019, 288, 146-155.[10]TangZH, PengJ,RenZ.et al.New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway[J]. Atherosclerosis, 2017, 262, 113-122.[11]Almontashiri NA, Vilmundarson RO, Ghasemzadeh N, et al. Plasma PCSK9 levels are elevated with acute myocardialinfarction in two independent retrospective angiographic studies. PLoS ONE.(2014) 9:e106294.[12]Li S, Zhang Y, Xu RX, et al. Proprotein convertase subtilisin-kexin type 9 as a biomarkerfor the severity of coronary artery disease[J]. AnnMed,2015,47:386–93[13]ialal I, Devaraj S, Venugopal SK. C-reactive protein: riskmarker or mediator in atherothrombosis?[J]. Hypertension,2004,44:6–11.[14]Pradhan AD, Aday AW, Rose LM, Ridker PM. Residual inflammatory risk on treatmentwithPCSK9inhibitionand statin therapy. Circulation. [J],2018,138:141–9[15]Bohula EA, Giugliano RP, Leiter LA, Verma S, et al.Inflammatory and cholesterol risk in the FOURIER trial[J]. Circulation 2018,138:131–140.[16]KoskinasK C, WindeckerS, Pedrazzini G, et al. Evolocumab for Early Reduction ofLDLCholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) [J]. J Am Coll Cardiol. 2019, 74(20): 2452-2462.[17]O'Donoghue ML, Giugliano RP, Wiviott SD,et al. Long-Term Evolocumab in Patientswith Established Athero-sclerotic Cardiovascular Disease[publishedonlineaheadofprint,202Aug29].Circulation,2022,10.1161/CIRCULATIONAHA.122.061620.[18]高霏,马晓腾,王志坚,杨丽霞,申华,李月平,史冬梅,周玉杰.他汀类药物联合阿利西尤单抗对血脂不达标的冠心病患者冠状动脉斑块结构和稳定性的影响[J].中国医药,2021,16(11):1618-1621.[19]Schwartz GG,StegPG,Szarek M, et al. Alirocumab and Cardiovascular Outcomes after AcuteCoronary Syndrome[J]. N Engl J Med. 2018;379(22):2097-2107.[20]GürgözeMT,Muller-Hansma AHG,Schreuder MM,etal.AdverseEvents Associated With PCSK9 Inhibitors: A Real-World Experience[J]. Clin Pharmacol Ther. 2019;105(2):496-504.